Insider · CIK 0002092593
Mark James Daniel
Files at ATOS (ATOSSA THERAPEUTICS, INC.). First filing -, latest -.
Mark James Daniel files SEC Form 4 as CFO at ATOS (ATOSSA THERAPEUTICS, INC.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Mark James Daniel has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 2 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Mar 26, 2026 | ATOS ATOSSA THERAPEUTICS, INC. | AGrant or award Common Stock | +63,000 | $0.00 | $0 | 63,000 | Mar 30, 2026 |
| Oct 14, 2025 | ATOS ATOSSA THERAPEUTICS, INC. | AGrant or award Stock Option (right to buy)derivative | +578,000 | $0.00 | $0 | 578,000 | Oct 21, 2025 |
Questions about Mark James Daniel
Answered from the filings on this page, as of the latest one.
Is Mark James Daniel buying or selling?
Mark James Daniel has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Mark James Daniel's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Mark James Daniel has 0.
Where does Mark James Daniel file Form 4?
Mark James Daniel has filed Form 4 at ATOS (ATOSSA THERAPEUTICS, INC.) as Chief Financial Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.